Connection

David Cole to Animals

This is a "connection" page, showing publications David Cole has written about Animals.
Connection Strength

0.741
  1. Effect of administration timing of postchemotherapy granulocyte colony-stimulating factor on host-immune cell recovery and CD8+ T-cell response. J Immunotoxicol. 2016 11; 13(6):784-792.
    View in: PubMed
    Score: 0.040
  2. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother. 2015 May; 64(5):539-49.
    View in: PubMed
    Score: 0.036
  3. Soluble IL-15/IL-15Ra complexes in human serum. Blood. 2012 Jul 05; 120(1):1-2.
    View in: PubMed
    Score: 0.030
  4. Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. Cell Immunol. 2012 Mar-Apr; 276(1-2):67-74.
    View in: PubMed
    Score: 0.029
  5. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012 Apr; 214(4):700-7; discussion 707-8.
    View in: PubMed
    Score: 0.029
  6. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol. 2010 Feb 15; 184(4):1737-47.
    View in: PubMed
    Score: 0.025
  7. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell Immunol. 2010; 261(2):134-43.
    View in: PubMed
    Score: 0.025
  8. Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination. Cancer Immunol Immunother. 2010 Mar; 59(3):341-53.
    View in: PubMed
    Score: 0.025
  9. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol. 2009 Feb 15; 182(4):2030-40.
    View in: PubMed
    Score: 0.024
  10. The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into na?ve recipient mice. Vaccine. 2009 Jan 22; 27(4):549-57.
    View in: PubMed
    Score: 0.023
  11. Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo. Cancer Gene Ther. 2009 Feb; 16(2):171-83.
    View in: PubMed
    Score: 0.023
  12. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother. 2007 Jan; 30(1):40-53.
    View in: PubMed
    Score: 0.020
  13. Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J Interferon Cytokine Res. 2006 Sep; 26(9):593-608.
    View in: PubMed
    Score: 0.020
  14. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine. 2006 Jun 12; 24(24):5119-32.
    View in: PubMed
    Score: 0.020
  15. Bystander effect contributes to the antitumor efficacy of CaSm antisense gene therapy in a preclinical model of advanced pancreatic cancer. Mol Ther. 2006 Feb; 13(2):357-65.
    View in: PubMed
    Score: 0.019
  16. Establishing a murine pancreatic cancer CaSm model: up-regulation of CaSm is required for the transformed phenotype of murine pancreatic adenocarcinoma. Mol Ther. 2005 Mar; 11(3):363-72.
    View in: PubMed
    Score: 0.018
  17. CaSm antisense gene therapy: a novel approach for the treatment of pancreatic cancer. Anticancer Res. 2003 May-Jun; 23(3A):2007-13.
    View in: PubMed
    Score: 0.016
  18. Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity. J Immunol. 2003 Feb 01; 170(3):1209-17.
    View in: PubMed
    Score: 0.016
  19. The cancer-associated Sm-like oncogene: a novel target for the gene therapy of pancreatic cancer. Surgery. 2000 Aug; 128(2):353-60.
    View in: PubMed
    Score: 0.013
  20. A pilot study evaluating the efficacy of a fully acetylated poly-N-acetyl glucosamine membrane formulation as a topical hemostatic agent. Surgery. 1999 Sep; 126(3):510-7.
    View in: PubMed
    Score: 0.012
  21. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Clin Cancer Res. 1999 May; 5(5):1173-82.
    View in: PubMed
    Score: 0.012
  22. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. Cancer Res. 2018 06 01; 78(11):3067-3074.
    View in: PubMed
    Score: 0.011
  23. IL-2 and Beyond in Cancer Immunotherapy. J Interferon Cytokine Res. 2018 02; 38(2):45-68.
    View in: PubMed
    Score: 0.011
  24. Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Clin Cancer Res. 1997 Jun; 3(6):867-73.
    View in: PubMed
    Score: 0.011
  25. Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. Cancer Immunol Immunother. 2017 Jun; 66(6):737-751.
    View in: PubMed
    Score: 0.010
  26. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. J Hepatol. 2017 01; 66(1):75-85.
    View in: PubMed
    Score: 0.010
  27. Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance. Cancer Immunol Res. 2016 09 02; 4(9):799-811.
    View in: PubMed
    Score: 0.010
  28. Lack of p53 Augments Antitumor Functions in Cytolytic T Cells. Cancer Res. 2016 09 15; 76(18):5229-5240.
    View in: PubMed
    Score: 0.010
  29. Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. Hum Gene Ther. 1996 Jul 10; 7(11):1381-94.
    View in: PubMed
    Score: 0.010
  30. IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. 2015 Oct 28; 7(311):311ra170.
    View in: PubMed
    Score: 0.009
  31. Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Ra Dependent. Cancer Immunol Res. 2015 Dec; 3(12):1364-74.
    View in: PubMed
    Score: 0.009
  32. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. J Control Release. 2015 Oct 28; 216:103-10.
    View in: PubMed
    Score: 0.009
  33. IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells. Cancer Gene Ther. 2015 Jul; 22(7):360-7.
    View in: PubMed
    Score: 0.009
  34. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clin Cancer Res. 2015 Jun 01; 21(11):2546-57.
    View in: PubMed
    Score: 0.009
  35. The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol. 2015 Feb 15; 194(4):1737-47.
    View in: PubMed
    Score: 0.009
  36. Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors. J Control Release. 2014 Mar 28; 178:79-85.
    View in: PubMed
    Score: 0.008
  37. Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors. Curr Cancer Drug Targets. 2014; 14(1):70-8.
    View in: PubMed
    Score: 0.008
  38. G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses. J Hematol Oncol. 2013 Oct 01; 6:75.
    View in: PubMed
    Score: 0.008
  39. Combined therapy with dizocilpine and levemopamil does not reduce ischemic neuronal injury in rats. J Neurosurg Anesthesiol. 1993 Jul; 5(3):194-201.
    View in: PubMed
    Score: 0.008
  40. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr; 20(4):222-8.
    View in: PubMed
    Score: 0.008
  41. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol. 2012 Aug 15; 189(4):1627-38.
    View in: PubMed
    Score: 0.008
  42. CD8(+) T cells sabotage their own memory potential through IFN-?-dependent modification of the IL-12/IL-15 receptor a axis on dendritic cells. J Immunol. 2012 Apr 15; 188(8):3639-47.
    View in: PubMed
    Score: 0.007
  43. A comparison of the cerebral protective effects of isoflurane and mild hypothermia in a model of incomplete forebrain ischemia in the rat. Anesthesiology. 1992 Feb; 76(2):221-8.
    View in: PubMed
    Score: 0.007
  44. Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. J Surg Res. 2012 Aug; 176(2):359-66.
    View in: PubMed
    Score: 0.007
  45. Induced hypertension during restoration of flow after temporary middle cerebral artery occlusion in the rat: effect on neuronal injury and edema. Surg Neurol. 1991 Sep; 36(3):195-201.
    View in: PubMed
    Score: 0.007
  46. Poly-N-acetyl glucosamine gel matrix as a non-viral delivery vector for DNA-based vaccination. Anticancer Res. 2010 Oct; 30(10):3889-94.
    View in: PubMed
    Score: 0.007
  47. CaSm (LSm-1) overexpression in lung cancer and mesothelioma is required for transformed phenotypes. Am J Respir Cell Mol Biol. 2008 Jun; 38(6):671-8.
    View in: PubMed
    Score: 0.006
  48. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol Immunother. 2008 Apr; 57(4):563-72.
    View in: PubMed
    Score: 0.005
  49. CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability. Cancer Res. 2005 Jul 15; 65(14):6228-36.
    View in: PubMed
    Score: 0.005
  50. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother. 2005 May-Jun; 28(3):220-8.
    View in: PubMed
    Score: 0.005
  51. Comparison of poly-N-acetyl glucosamine with commercially available topical hemostats for achieving hemostasis in coagulopathic models of splenic hemorrhage. J Trauma. 2004 Jul; 57(1 Suppl):S29-32.
    View in: PubMed
    Score: 0.004
  52. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol. 2004 May 01; 172(9):5159-67.
    View in: PubMed
    Score: 0.004
  53. Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine. 2003 Jun 02; 21(19-20):2318-28.
    View in: PubMed
    Score: 0.004
  54. CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol. 2003 Mar 01; 170(5):2582-9.
    View in: PubMed
    Score: 0.004
  55. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. J Immunother. 2001 Sep-Oct; 24(5):420-9.
    View in: PubMed
    Score: 0.004
  56. Identification of a T-cell receptor from a therapeutic murine T-cell clone. J Immunother. 1997 Jul; 20(4):247-55.
    View in: PubMed
    Score: 0.003
  57. Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema. Acta Neuropathol. 1991; 81(3):339-44.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.